(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...